NCT05789576

A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

A Phase 4, Open-label Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in the Treatment of Plaque Psoriasis Occurring in the Head and Neck Region

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region

Detailed description

This is an open-label study in which participants with plaque psoriasis in the head and neck region will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	VTAMA (tapinarof) cream, 1%	VTAMA (tapinarof) cream, 1% applied topically once daily

Timeline

• Start date: 2023-03-13
• Primary completion: 2023-06-30
• Completion: 2023-07-19
• First posted: 2023-03-29
• Last updated: 2025-06-12
• Results posted: 2024-08-09

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study